Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Netherton Syndrome

Interventions

DRUG: QRX003-2% Lotion
DRUG: QRX003-4% Lotion QAM
DRUG: Vehicle
DRUG: QRX003-4% Lotion BID

Sponsor

Quoin Pharmaceuticals